Psoriatic Arthritis – Landscape & Forecast – Disease Landscape & Forecast

The psoriatic arthritis (PsA) therapy market has become increasingly dynamic with the recent launches of several targeted agents—AbbVie’s Rinvoq and Skyrizi and UCB’s bimekizumab. Furthermore, a series of approvals expected in the next decade will likely present a challenge to the dominance of the TNF inhibitors, especially as biosimilars are increasingly accepted as alternatives to more-expensive branded therapies, and drugs with novel mechanisms of action become available. Interleukin (IL)-17 and IL-23 inhibitors, in particular, are poised to garner substantial sales and, with the diagnosis and drug-treatment rate anticipated to remain relatively steady, could threaten the positions of current market leaders. The impending entry of the first TYK2 inhibitor (BMS’s deucravacitinib) and an IL-23 inhibitor (Sun Pharma’s tildrakizumab) will also create interesting market dynamics.

Questions answered

  • What impact will current and emerging biosimilars have on the PsA therapy market in the coming years? How will physicians in the various markets under study react to these less-expensive therapies?
  • How will newer agents, especially those offering an alternative to the market-leading TNF inhibitors, change the PsA therapy market? What are physician perceptions of these therapies?
  • Which emerging therapies do dermatologists and rheumatologists consider the most promising for PsA? Which novel mechanisms of action are considered good clinical targets for this disease?
  • Which unmet needs remain in the treatment of PsA? Will emerging therapies fulfill these needs, and will they be competitive with biosimilars and entrenched branded therapies?

Content highlights:

Geographies: United States, EU5, Japan.

Primary research: 31 country-specific interviews with thought-leading dermatologists and rheumatologists supported by survey data collected for this and other Clarivate research.

Epidemiology: Number of PsA patients by country, including diagnosed and drug-treated populations.

Forecast: 10-year, annualized, drug-level sales and patient share of key PsA therapies to 2032, segmented by brands / generics.

Emerging therapies: Phase 3/PR: 2 drugs; Phase 2: 7 drugs.

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Disease Landscape & Forecast is updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents